TNXP News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TN

Mkt Cap

$103.9M

Volume

889.04K

Next Earnings

November 9th

Loading chart

TN

TNXPTonix Pharmaceuticals Holding Corp.

TNXP

Pay with—

Available Balance0.00

TN

Mkt Cap

$110.1M

Volume

889.03K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. LivesTonix Pharmaceuticals announced a second commercial payer agreement with a leading GPO effective June 1, 2026, providing coverage for TONMYA® to approximately 17 million additional U.S. commercial lives. Combined with the first agreement announced in May 2026, TONMYA now has commercial coverage for approximately 52 million U.S. lives (29% of total commercial lives). TONMYA is the first new fibromyalgia medicine approved by the FDA in over 15 years and is also available under Medicaid in most states covering approximately 75 million lives.GlobeNewswire Inc. · Jun 8, 2026

Bay Area Lyme Foundation Raises $900,000 at LymeAid 2026, Presenting Inaugural Neil L. Spector, MD, Legacy Award and $300,000 in Emerging Leader GrantsBay Area Lyme Foundation raised $900,000 at its annual LymeAid 2026 gala, featuring entertainment by Dana Carvey and Chris Isaak. The foundation presented its inaugural Neil L. Spector, MD, Legacy Award to Timothy Haystead, PhD, and distributed $300,000 in Emerging Leader Awards to researchers studying Lyme disease diagnostics and tick-borne infections. Bay Area Lyme Ventures expanded its portfolio with a new investment in Galaxy Diagnostics.GlobeNewswire Inc. · May 28, 2026

Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026 featuring a retrospective U.S. real-world claims analysis of fibromyalgia patients using data from April 2021-April 2024. TONMYA (cyclobenzaprine HCl sublingual tablets), approved by the FDA on August 15, 2025, and commercially launched on November 17, 2025, is the first new prescription medicine for fibromyalgia in over 15 years. The company also reported strong Q1 2026 results with 2,145 healthcare providers prescribing TONMYA, 3,588 patients initiated treatment, and approximately 5,400 prescriptions filled.GlobeNewswire Inc. · May 14, 2026

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug DevelopmentTonix Pharmaceuticals announced the publication of pharmacokinetic data for TONMYA (cyclobenzaprine HCl sublingual tablets) in the peer-reviewed journal Clinical Pharmacology in Drug Development. The study demonstrated that TONMYA, the first new FDA-approved fibromyalgia treatment in over 15 years (approved August 2025, commercially launched November 2025), achieved steady-state pharmacokinetics at Day 20 with rapid absorption and higher bioavailability per dose compared to oral extended-release cyclobenzaprine. The sublingual formulation was generally safe and well-tolerated with no serious adverse events.GlobeNewswire Inc. · Apr 15, 2026

Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026Tonix Pharmaceuticals announced that CEO Seth Lederman will deliver a company presentation at BIO-Europe Spring 2026 in Lisbon on March 24, 2026. The presentation will highlight the company's commercial-stage biotechnology portfolio focused on CNS and immunology treatments, including TONMYA® for fibromyalgia (launched November 2025 with over 1,500 prescriptions), acute migraine products, and pipeline candidates in development.GlobeNewswire Inc. · Mar 18, 2026

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics SummitTonix Pharmaceuticals presented Phase 3 RESILIENT trial data for TONMYA, a sublingual cyclobenzaprine formulation for fibromyalgia treatment. The drug demonstrated statistically significant reduction in pain (p<0.0001) and improvements in sleep disturbance, fatigue, and functional outcomes compared to placebo. TONMYA was well-tolerated with minimal weight and blood pressure effects, though oral cavity reactions were the most common adverse events. The drug was FDA-approved in August 2025 as the first new fibromyalgia prescription in over 15 years.GlobeNewswire Inc. · Jan 30, 2026

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive DisorderTonix Pharmaceuticals received FDA clearance to proceed with a Phase 2 HORIZON study of TNX-102 SL, a potential new treatment for major depressive disorder, targeting 360 patients across 30 U.S. sites with planned enrollment in mid-2026.GlobeNewswire Inc. · Nov 24, 2025

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia TreatmentTonix Pharmaceuticals launched TONMYA, the first FDA-approved fibromyalgia treatment in over 15 years, offering a novel, non-opioid, once-daily bedtime analgesic for the estimated 10 million adults suffering from the chronic pain disorder.GlobeNewswire Inc. · Nov 17, 2025

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ RejectionTonix Pharmaceuticals is collaborating with Massachusetts General Hospital to conduct a Phase 2 clinical trial of TNX-1500, a monoclonal antibody designed to prevent kidney transplant rejection with potentially reduced immunosuppressive drug side effects.GlobeNewswire Inc. · Nov 4, 2025

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) ConvergenceTonix Pharmaceuticals presented Phase 3 RESILIENT study data on Tonmya, demonstrating significant pain reduction in fibromyalgia patients with minimal side effects. The drug was FDA-approved in August 2025 and shows promise as a well-tolerated, non-opioid treatment.GlobeNewswire Inc. · Oct 27, 2025

to start trading

TN

TNXPTonix Pharmaceuticals Holding Corp.

TNXP

Pay with—

Available Balance0.00

Your PositionYou don't own any TNXP yet.

Related Tickers

Earnings